Treating Bipolar Depression Using Psilocybin—Validity Threats Regarding Efficacy and Safety

JAMA Psychiatry, vol. 81, pp. 633

Abstract

To the Editor According to the study protocol, the recently published study by Aaronson et al1 was carried out “to assess effectiveness of 25 mg of psilocybin in [15] patients with treatment-resistant type 2 bipolar depression.” We see 3 concerns.

Authors 3

1. Eiko I. Fried Aachen Department of Psychology, Clinical Psychology Unit

   Leiden University

   Affiliation as printed

   Department of Psychology, Clinical Psychology Unit, Leiden University, Leiden, the Netherlands

   Universiteit Leiden = Leiden University (Leiden University | 2300 RA Leiden The Netherlands - Netherlands)

2. Ioana A. Cristea

   University of Padua

   Affiliation as printed

   Department of General Psychology, University of Padova, Padova, Italy

   Unipd - Università degli Studi di Padova = University of Padua (Via 8 Febbraio 2, 35122 Padova - Italy)

3. Florian Naudet

   Inserm · Centre Hospitalier Universitaire de Rennes · Université de Rennes · Institut de Recherche en Santé, Environnement et Travail

   Affiliation as printed

   University of Rennes, University Hospital of Rennes, Inserm, Institut de recherche en santé, environnement et travail, Rennes, France

   Centre Hospitalier Universitaire [Rennes] (rue H. Le Guillou 35033 Rennes - France)

   Irset - Institut de recherche en santé, environnement et travail (263 avenue Général Leclerc 35042 Rennes Cedex - France)